FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090899812> ?p ?o ?g. }

• W2090899812 endingPage "2947" @default.
• W2090899812 startingPage "2947" @default.
• W2090899812 abstract "Blacks are disproportionately affected by stroke, and they are about 2 times more likely than most other individuals in the United States to die of or experience stroke.To determine the efficacy and safety of aspirin and ticlopidine to prevent recurrent stroke in black patients.Randomized, double-blind, investigator-initiated, multicenter trial of 1809 black men and women who recently had a noncardioembolic ischemic stroke and who were recruited between December 1992 and October 2001 from 62 academic and community hospitals in the United States and followed up for up to 2 years.A total of 902 patients received 500 mg/d of ticlopidine and 907 received 650 mg/d of aspirin.Recurrent stroke, myocardial infarction, or vascular death was the composite primary end point (according to intention-to-treat analysis). The secondary outcome was fatal or nonfatal stroke.The blinded phase of the study was halted after about 6.5 years when futility analyses revealed a less than 1% probability of ticlopidine being shown superior to aspirin in the prevention of the primary outcome end point. The primary outcome of recurrent stroke, myocardial infarction, or vascular death was reached by 133 (14.7%) of 902 patients assigned to ticlopidine and 112 (12.3%) of 907 patients assigned to aspirin (hazard ratio, 1.22; 95% confidence interval, 0.94-1.57). Kaplan-Meier curves for time to event for the primary outcome did not differ significantly (P =.12 by log-rank test). Kaplan-Meier curves for time to the secondary outcome of fatal or nonfatal stroke approached a statistically significant reduction favoring aspirin over ticlopidine (P =.08 by log-rank test). The frequency of laboratory-determined serious neutropenia was 3.4% for patients receiving ticlopdine vs 2.2% for patients receiving aspirin (P =.12) and 0.3% vs 0.2% for thrombocytopenia, respectively (P =.69). One ticlopidine-treated patient developed thrombocytopenia, which was thought to be a case of possible thrombotic thrombocytopenia purpura, and recovered after therapy with plasmapheresis.During a 2-year follow-up, we found no statistically significant difference between ticlopidine and aspirin in the prevention of recurrent stroke, myocardial infarction, or vascular death. However, there was a nonsignificant trend for reduction of fatal or nonfatal stroke among those in the aspirin group. Based on these data and the risk of serious adverse events with ticlopidine, we regard aspirin as a better treatment for aspirin-tolerant black patients with noncardioembolic ischemic stroke." @default.
• W2090899812 created "2016-06-24" @default.
• W2090899812 creator A5019914929 @default.
• W2090899812 date "2003-06-11" @default.
• W2090899812 modified "2023-10-13" @default.
• W2090899812 title "Aspirin and Ticlopidine for Prevention of Recurrent Stroke in Black Patients<SUBTITLE>A Randomized Trial</SUBTITLE>" @default.
• W2090899812 cites W10902558 @default.
• W2090899812 cites W126117316 @default.
• W2090899812 cites W149071441 @default.
• W2090899812 cites W1555222532 @default.
• W2090899812 cites W1580788756 @default.
• W2090899812 cites W1966183137 @default.
• W2090899812 cites W1971442835 @default.
• W2090899812 cites W1977167069 @default.
• W2090899812 cites W1985595174 @default.
• W2090899812 cites W1997869880 @default.
• W2090899812 cites W2015990163 @default.
• W2090899812 cites W2024352468 @default.
• W2090899812 cites W2027538725 @default.
• W2090899812 cites W2028273629 @default.
• W2090899812 cites W2038785074 @default.
• W2090899812 cites W2079234447 @default.
• W2090899812 cites W2083065622 @default.
• W2090899812 cites W2101085085 @default.
• W2090899812 cites W2126212628 @default.
• W2090899812 cites W2127074707 @default.
• W2090899812 cites W2131130199 @default.
• W2090899812 cites W2137835206 @default.
• W2090899812 cites W2144504916 @default.
• W2090899812 cites W2148132508 @default.
• W2090899812 cites W2148958485 @default.
• W2090899812 cites W2158431771 @default.
• W2090899812 cites W2169639211 @default.
• W2090899812 cites W2188590459 @default.
• W2090899812 cites W2318352361 @default.
• W2090899812 cites W2318964137 @default.
• W2090899812 cites W2333592939 @default.
• W2090899812 cites W2492141817 @default.
• W2090899812 cites W311320695 @default.
• W2090899812 cites W3205926832 @default.
• W2090899812 cites W1989154016 @default.
• W2090899812 cites W2000137303 @default.
• W2090899812 cites W2030189178 @default.
• W2090899812 doi "https://doi.org/10.1001/jama.289.22.2947" @default.
• W2090899812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12799402" @default.
• W2090899812 hasPublicationYear "2003" @default.
• W2090899812 type Work @default.
• W2090899812 sameAs 2090899812 @default.
• W2090899812 citedByCount "223" @default.
• W2090899812 countsByYear W20908998122012 @default.
• W2090899812 countsByYear W20908998122013 @default.
• W2090899812 countsByYear W20908998122014 @default.
• W2090899812 countsByYear W20908998122015 @default.
• W2090899812 countsByYear W20908998122016 @default.
• W2090899812 countsByYear W20908998122017 @default.
• W2090899812 countsByYear W20908998122018 @default.
• W2090899812 countsByYear W20908998122019 @default.
• W2090899812 countsByYear W20908998122020 @default.
• W2090899812 countsByYear W20908998122021 @default.
• W2090899812 countsByYear W20908998122022 @default.
• W2090899812 countsByYear W20908998122023 @default.
• W2090899812 crossrefType "journal-article" @default.
• W2090899812 hasAuthorship W2090899812A5019914929 @default.
• W2090899812 hasConcept C126322002 @default.
• W2090899812 hasConcept C127413603 @default.
• W2090899812 hasConcept C141071460 @default.
• W2090899812 hasConcept C164705383 @default.
• W2090899812 hasConcept C168563851 @default.
• W2090899812 hasConcept C203092338 @default.
• W2090899812 hasConcept C207103383 @default.
• W2090899812 hasConcept C2777628954 @default.
• W2090899812 hasConcept C2777849778 @default.
• W2090899812 hasConcept C2778905298 @default.
• W2090899812 hasConcept C2780645631 @default.
• W2090899812 hasConcept C44249647 @default.
• W2090899812 hasConcept C500558357 @default.
• W2090899812 hasConcept C71924100 @default.
• W2090899812 hasConcept C78519656 @default.
• W2090899812 hasConceptScore W2090899812C126322002 @default.
• W2090899812 hasConceptScore W2090899812C127413603 @default.
• W2090899812 hasConceptScore W2090899812C141071460 @default.
• W2090899812 hasConceptScore W2090899812C164705383 @default.
• W2090899812 hasConceptScore W2090899812C168563851 @default.
• W2090899812 hasConceptScore W2090899812C203092338 @default.
• W2090899812 hasConceptScore W2090899812C207103383 @default.
• W2090899812 hasConceptScore W2090899812C2777628954 @default.
• W2090899812 hasConceptScore W2090899812C2777849778 @default.
• W2090899812 hasConceptScore W2090899812C2778905298 @default.
• W2090899812 hasConceptScore W2090899812C2780645631 @default.
• W2090899812 hasConceptScore W2090899812C44249647 @default.
• W2090899812 hasConceptScore W2090899812C500558357 @default.
• W2090899812 hasConceptScore W2090899812C71924100 @default.
• W2090899812 hasConceptScore W2090899812C78519656 @default.
• W2090899812 hasIssue "22" @default.
• W2090899812 hasLocation W20908998121 @default.
• W2090899812 hasLocation W20908998122 @default.
• W2090899812 hasOpenAccess W2090899812 @default.
• W2090899812 hasPrimaryLocation W20908998121 @default.

• next